Canada to potentially join parallel Scientific Advice with EMA and FDA for Complex Generics
Three years ago The FDA and the European Medicines Agency (EMA) have initiated a pilot program aimed at offering parallel scientific...
Phortas is Thrilled to Announce Our Participation at BioSpain 2023!
At Phortas, we are excited to share some remarkable news with you - we will be attending BioSpain 2023, one of Europe's premier...
What to keep in mind as a developer of Drugs for Rare Diseases?
The definition of rare disease varies across countries and jurisdictions, but it usually takes into account disease prevalence, severity...